دورية أكاديمية
GATA 3 Expression in Locally Advanced Breast Cancer and its Association with Prognostic Markers.
| العنوان: | GATA 3 Expression in Locally Advanced Breast Cancer and its Association with Prognostic Markers. |
|---|---|
| المؤلفون: | V., Sachin, S., Akash Nayak, R., Abhinandan, Raghavendra, Shreya |
| المصدر: | Journal of Cardiovascular Disease Research (Journal of Cardiovascular Disease Research); 2024, Vol. 15 Issue 8, p1341-1351, 11p |
| مستخلص: | Background Breast cancer is the most common cancer in Indian women, with a mortality rate of 12.7 per 100,000 women and an age adjusted incidence of up to 25.8 per 100,000 women. The breast cancer projection for India in 2020 predicts a potential occurrence of up to 1,797,900 cases. (1) Breast cancer incidence peaks in the 40–50 years age group in Indian women. Most of these cancers are HER2 positive and ER/PR negative, or triple negative, with poor prognosis.(2)In developing nations, the majority of breast cancer cases are detected at an advanced stage, and 50% of patients undergoing certain treatments have locally advanced breast cancer (3) The current methods of treatment consist of surgery, radiotherapy, chemotherapy, and hormonal therapy. Hormone treatment is determined by the tumor tissue's hormone receptor (ER, PR) status. The objective of this study is to establish a relationship between expression of conventional hormone receptors and HER-2/neu status and GATA 3 expression. this study also aims to find associations if any between GATA 3 expression and AJCC 8th edition prognostic staging. Methods This prospective study included 30 locally advanced breast cancer patients admitted to KR Hospital Mysuru (Mysore) from September 2022 to March 2024. Age, gender, lump duration, parity, and clinical stage were recorded, BIRADS score, pathological type, stage, grade, ER, PR, and HER2/Neu status were determined. The AJCC 8th edition breast carcinoma staging guidelines were used for clinical, pathological, and prognostic staging. Postoperative histopathological Parafin blocks were stained with GATA 3 on microarray slides. Data was tabulated and coded in Microsoft® Excel before IBM® SPSS ver18.0 statistical analysis. Results This study examined 30 clinical/pathological locally advanced breast cancer cases, focusing on GATA 3 expression and its relationship with prognostic factors and hormone receptors. The majority of patients were women (96.7%). They were 46–60 years old and 37% had clinical stage 3B. 86% had invasive ductal carcinoma and 84% were moderately to poorly differentiated. About 50% of patients were HER2 positive, while 80% were ER and PR positive. GATA 3 expression was measured using immunohistochemistry, resulting in a mean score of 17.4 ± 12.048. ER-positive tumors had significantly higher GATA 3 scores (19.8 ± 11.4) compared to ER-negative tumors (5.2 ± 7.3), with a significant correlation (p = 0.012). GATA 3 predicted ER status with 76.7% accuracy and 75% to 99.8% sensitivity. The relationship between GATA 3 positivity and PR status was not significant (p = 0.141). A significant correlation (p=0.011) showed higher GATA 3 scores for PR-positive. GATA 3 scores were higher in HER2-positive tumors (22.1 ± 10.6) compared to HER2-negative tumors (13.3 ± 12.5), but the correlation was weaker (p = 0.044). The GATA 3 scores did not vary with clinical or pathological stages, suggesting they may not be reliable indicators. Further research is needed on these findings. Conclusion The study demonstrates that GATA 3 expression is significantly associated with ER and PR status, making it a valuable marker for these receptors. However, GATA 3's role in predicting clinical or pathological stages is less clear, as it does not show strong correlations with these prognostic factors. The high sensitivity of GATA 3 for ER status suggests it could be a useful tool in identifying ER-positive tumors. The findings also highlight the need for further research to explore the potential role of GATA 3 in HER2-positive tumors and its overall utility in breast cancer prognosis [ABSTRACT FROM AUTHOR] |
| Copyright of Journal of Cardiovascular Disease Research (Journal of Cardiovascular Disease Research) is the property of Journal of Cardiovascular Disease Research and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| قاعدة البيانات: | Complementary Index |
كن أول من يترك تعليقا!